1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sprint Bioscience AB

Sprint Bioscience AB

3.35
SEK
-0.25
(-6.94%)
0.72EPS
5.77P/E
436.83MMarket Cap
Nov 11Next Earn
Sprint Bioscience AB
STO:SPRINT
(Nasdaq Stockholm)

Recent

price

3.35

P/E

ratio

5.77

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
1.39
0.23
0.34
- -
0.87
3.77
2.4
1.49
2.38
0.89
1
- -
0.71
0.94
1.81
1.32
Revenue per Share
-0.81
-0.52
-0.64
-1.29
-1.74
0.49
-1.07
-2.65
-1.53
-2.25
-0.71
- -
-0.01
-0.26
0.99
0.72
Basic EPS, GAAP
- -
-0.72
-1.17
-1.66
-0.6
-0.21
-3.18
-2.5
-2
-1.7
-1.22
- -
0.29
-0.35
0.9
0.64
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.3
0.16
0.49
2.28
0.54
2.96
2.72
-0.11
0.65
0.34
1.48
0.4
0.39
0.13
1.13
0.85
Book Value per Share
0.3
-0.18
-0.38
1.21
-1.13
0.81
-0.1
-2.93
0.65
0.34
1.48
0.4
0.39
0.13
1.13
0.85
Tangible Book Value per Share
2
7
7
9
9
9
10
12
14
19
35
43
71
70
93
106
Basic Weighted Avg Shares
2
2
2
- -
8
35
24
18
34
17
35
- -
50
66
167
139
Sales/Revenue/Turnover
-65.1
-329.79
-175.32
- -
-195.88
12.58
-43.1
-177.09
-60.88
-223.13
-72.52
- -
-5.01
-29.57
58.35
56.22
Operating Margin (%)
- -
- -
- -
- -
- -
3
1
1
1
1
1
- -
- -
1
1
1
Depreciation Expense
-1
-4
-4
-11
-16
5
-11
-32
-22
-43
-25
- -
- -
-18
92
76
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-58.15
-223.3
-185.03
- -
-200.61
12.98
-44.49
-177.82
-64.21
-253.43
-71.43
- -
-0.87
-27.84
54.88
54.37
Profit Margin (%)
- -
-1
-1
12
-10
6
-3
-4
9
8
67
26
23
4
115
86
Working Capital
- -
1
2
2
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
2
1
3
20
5
28
28
-2
11
9
70
28
28
9
119
90
Total Equity
- -
- -
- -
- -
- -
25.59
- -
- -
- -
- -
- -
- -
- -
- -
151.49
149.87
Return on Invested Capital (%)
- -
- -
- -
- -
- -
25.97
- -
- -
- -
- -
- -
- -
- -
- -
143.5
154.68
Return on Capital (%)
- -
-226.9
-196.73
-96.81
-123.31
27.26
-37.69
- -
- -
-424.5
-63.02
- -
-1.57
-98.67
142.84
144.94
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
106
106
106
Market Capitalization
155
251
437

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
133
115
101
Cash, Cash Equivalents & STI
127
108
93
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
17
13
14
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
127.4%
345.55%
1,185.34%
Free Cash Flow
- -
- -
-438.45%
Net Income, GAAP
- -
- -
-601.92%
Sales/Revenue/Turnover
- -
- -
154.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
18
17
15
16
66
2025
14
14
5
134
167
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
-0.08
-0.07
-0.06
-0.26
2025
-0.08
-0.08
-0.08
1.07
0.99
2026
-0.12
-0.15
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sprint Bioscience AB (publ) is a biotechnology company specializing in drug discovery and development services primarily focused on oncology. The company offers a comprehensive drug discovery platform that includes target identification and validation, small molecule screening, hit-to-lead optimization, and preclinical development services. Its core products and services consist of proprietary drug discovery technologies, enabling partners to advance novel cancer therapies, along with collaborative research and development partnerships. Sprint Bioscience operates in the life sciences and pharmaceutical industry, serving pharmaceutical and biotech companies globally. Founded in 2001 and headquartered in Stockholm, Sweden, Sprint Bioscience leverages advanced scientific expertise and proprietary platforms to accelerate the development of innovative cancer treatments. The company actively engages in strategic collaborations and partnerships to expand its capabilities and reach. Recent major developments include new strategic alliances aimed at enhancing its drug discovery pipeline and broadening its service offerings, though no name changes or significant restructuring have been reported in the past two years. Sprint Bioscience continues to focus on improving its platform technologies and expanding its global research collaborations to drive the discovery of novel oncology drugs. The company's geographic operations span mainly Europe with a global client base, and it plays a significant role in the oncology drug discovery sector through its integration of cutting-edge science and collaborative models. Sprint Bioscience's services cover multiple stages of the drug discovery process, making it a key partner for pharmaceutical companies aiming to bring new cancer treatments to market. The company's ongoing investments in innovation and partnerships underline its commitment to advancing oncology therapeutics worldwide.